



Canada's Cannabis Legalization Brewing Some Interesting Partnerships as New Markets and Products Emerge and Corporate Update

VANCOUVER, BC, Thursday July 5, 2018 – EViTRADE Health Systems Corp. (CSE: EVA, OTCQB: AXHLF) (the “Company”). In the afterglow of Canada’s recent [legalization of recreational cannabis](#), news is coming out about some thought-provoking and eyebrow-raising partnerships between mainstream consumer products and cannabis producers. This emerging trend could portend good things for **EViTRADE Health Systems Corp.** (quoted in Canada on the Canadian Securities Exchange as CSE:EVA and quoted in the United States on the OTC Markets as OTCQB: AXHLF) as it looks to explore new avenues and expand revenue channels.

The market here is currently fizzing over proposed deals between beer giant Molson Coors (NYSE:TAP) and two Canadian cannabis companies that would [create cannabis-infused beverages](#). Molson Coors’ isn’t the first beverage maker to come up with the idea, just the latest. Rival brewer Constellation Brands (NYSE:STZ), whose roster includes Corona beer, has agreed [to buy a nearly 10 percent stake](#) in a cannabis company with thoughts towards a cannabis beverage of its own.

“These are clearly heady times in the cannabis industry,” said CK Cheung, CEO of Evitrade. “Thanks to pending legalization in Canada, scores of new markets and new cannabis-infused or related products are on the horizon. This emerging trend opens several exciting possibilities for companies like ours. We are definitely open to exploring partnerships with healthcare firms – or any type of consumer-oriented company – to develop and market new items.”

In addition to new corporate partnerships between beverage outfits and cannabis producers, banks are also now [loaning money to cannabis companies](#). This is providing [new capital into the industry](#) and could spur additional product research and development, opening more new markets.

Canada’s recreational cannabis market is expected to generate [\\$4.3 billion in revenues](#) following legalization in July 2018. Industry watchers expect that [to grow to \\$6 billion by 2021](#). Meanwhile, the already legal medicinal market represents [a \\$1.3 billion opportunity](#).

Corporate Update:

Plan of Arrangement: The trials division subsidiary, currently named Ecovatec Health Solutions Inc. is scheduled to be completed effective the week of July 9th, 2018;



**EViTRADE
Health
Systems
Corporation**

Artillery Labs transaction: The Company is still completing all due diligence and has been reviewing all assets and financial statements in order to finalize on the assets to be transferred, performance milestones and key person responsibilities that will be in effect upon closing. All transaction details shall be provided upon closing;

Cantech Molecular Research transaction: The Company is also completing its due diligence on the company and the assets to be transferred, financial statements and key person contributions and responsibilities that will be in effect upon closing. All transaction details shall be provided upon closing.

Contact: CK Cheung, Director

EViTRADE Health Systems Corporation
(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

US OTC Markets: <http://www.otcmarkets.com/stock/AXHLF/news>

About EVITRADE Health (CSE: EVA, OTCQB: AXHLF)

EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online “digital healthcare” services for resolving common health problems. The current markets are weight-management, high blood pressure, high blood glucose and heart arrhythmia.

Disclaimers – Forward Looking Statements

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <http://www.otcmarkets.com/stock/AXHLF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.